Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019.
France
MDR TB
XDR TB
antimicrobial resistance
bacteria
bedaquiline
linezolid
respiratory infections
tuberculosis
tuberculosis and other mycobacteria
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
entrez:
23
8
2022
pubmed:
24
8
2022
medline:
25
8
2022
Statut:
ppublish
Résumé
Definitions of resistance in multidrug-resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB) have been updated. Pre-XDR TB, defined as MDR TB with additional resistance to fluoroquinolones, and XDR TB, with additional resistance to bedaquiline or linezolid, are frequently associated with treatment failure and toxicity. We retrospectively determined the effects of pre-XDR/XDR TB resistance on outcomes and safety of MDR TB treatment in France. The study included 298 patients treated for MDR TB at 3 reference centers during 2006-2019. Of those, 205 (68.8%) cases were fluoroquinolone-susceptible MDR TB and 93 (31.2%) were pre-XDR/XDR TB. Compared with fluoroquinolone-susceptible MDR TB, pre-XDR/XDR TB was associated with more cavitary lung lesions and bilateral disease and required longer treatment. Overall, 202 patients (67.8%) had favorable treatment outcomes, with no significant difference between pre-XDR/XDR TB (67.7%) and fluoroquinolone-susceptible MDR TB (67.8%; p = 0.99). Pre-XDR/XDR TB was not associated with higher risk for serious adverse events.
Identifiants
pubmed: 35997386
doi: 10.3201/eid2809.220458
pmc: PMC9423894
doi:
Substances chimiques
Antitubercular Agents
0
Fluoroquinolones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1796-1804Investigateurs
Alexandra Aubry
(A)
Isabelle Bonnet
(I)
Johannes Eimer
(J)
Florence Morel
(F)
Nicolas Veziris
(N)
Emmanuelle Cambau
(E)
Emmanuel Lecorché
(E)
Faiza Mougari
(F)
Claire Andrejak
(C)
Anne Bourgarit
(A)
Elise Klement
(E)
Bénédicte Rivoire
(B)
Guillaume Thouvenin
(G)
Simone Tunesi
(S)
Marie Wicky
(M)
Marie Jaspard
(M)
Corentine Alauzet
(C)
Lelia Escaut
(L)
Sophie Ellis-Corbet
(S)
Anne-Laure Roux
(AL)
Références
Pulmonology. 2018 Mar - Apr;24(2):132-141
pubmed: 29229274
Eur Respir J. 2013 Jun;41(6):1393-400
pubmed: 23018916
Am J Respir Crit Care Med. 2021 Sep 15;204(6):713-722
pubmed: 34107231
Int J Tuberc Lung Dis. 2019 Oct 1;23(10):1060-1067
pubmed: 31627770
PLoS One. 2021 Apr 20;16(4):e0250028
pubmed: 33878119
Lancet. 2018 Sep 8;392(10150):821-834
pubmed: 30215381
N Engl J Med. 2019 Mar 28;380(13):1201-1213
pubmed: 30865791
Eur Respir J. 2016 Aug;48(2):582-5
pubmed: 27338196
Eur Respir J. 2018 Feb 21;51(2):
pubmed: 29467205
Int J Tuberc Lung Dis. 2019 Oct 1;23(10):1050-1054
pubmed: 31627768
Eur Respir J. 2013 Jul;42(1):156-68
pubmed: 23100499
Int J Tuberc Lung Dis. 2015 May;19(5):525-30
pubmed: 25868019
Clin Infect Dis. 2007 Nov 15;45(10):1290-5
pubmed: 17968823
Lancet Respir Med. 2020 Apr;8(4):383-394
pubmed: 32192585
N Engl J Med. 2020 Mar 5;382(10):893-902
pubmed: 32130813
J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):21-7
pubmed: 23075918
N Engl J Med. 2012 Oct 18;367(16):1508-18
pubmed: 23075177
N Engl J Med. 2014 Aug 21;371(8):723-32
pubmed: 25140958
PLoS Med. 2012;9(8):e1001300
pubmed: 22952439
Eur Respir J. 2015 Jan;45(1):161-70
pubmed: 25234807
Am J Respir Crit Care Med. 2018 Nov 1;198(9):1228-1231
pubmed: 29969054
Am J Respir Crit Care Med. 2008 Nov 15;178(10):1075-82
pubmed: 18703792
Int J Tuberc Lung Dis. 2021 May 1;25(5):395-399
pubmed: 33977908
Eur Respir J. 2021 Aug 19;58(2):
pubmed: 33926973
Open Forum Infect Dis. 2019 Apr 01;6(4):ofz118
pubmed: 30949546
Int J Tuberc Lung Dis. 2012 Oct;16(10):1335-43
pubmed: 23107633
N Engl J Med. 2015 Jul 16;373(3):290-1
pubmed: 26176401
Euro Surveill. 2013 Aug 15;18(33):20555
pubmed: 23968874